Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: cyclophosphamideBiological: epoetin alfaDrug: epirubicin hydrochlorideBiological: filgrastimDrug: doxorubicin hydrochlorideDrug: fluorouracilDrug: paclitaxel
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 2104
- Registration Number
- NCT00014222
- Locations
- 🇺🇸
Sparks-Arkansas Oklahoma Cancer Treatment Centre, Fort Smith, Arkansas, United States
🇺🇸Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00049101
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Intracel
- Registration Number
- NCT00016133
- Locations
- 🇺🇸
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸Inova Fairfax Hospital, Fairfax, Virginia, United States
Radiation Therapy and Fluorouracil Before Surgery in Treating Patients With Primary or Recurrent Bile Duct Cancer
- Conditions
- Extrahepatic Bile Duct CancerLiver Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Registration Number
- NCT00030511
- Locations
- 🇧🇪
Les Cliniques Saint-Joseph ASBL, Liege, Belgium
🇺🇸Cancer Center at the University of Virginia, Charlottesville, Virginia, United States
🇧🇪Hopital de Jolimont, Haine Saint Paul, Belgium
Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach
- Conditions
- Esophageal CancerGastric Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00009880
- Locations
- 🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Mount Carmel West Hospital, Columbus, Ohio, United States
Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Center for Molecular Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00002689
- Locations
- 🇺🇸
Northside Hospital Cancer Center, Atlanta, Georgia, United States
🇺🇸Center for Molecular Medicine, Garden City, New York, United States
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00045747
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
- Conditions
- Childhood HepatoblastomaRecurrent Childhood Liver CancerStage I Childhood Liver Cancer
- Interventions
- Procedure: therapeutic conventional surgeryDrug: cisplatinDrug: vincristine sulfateDrug: carboplatinDrug: fluorouracilDrug: amifostine trihydrate
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 277
- Registration Number
- NCT00003994
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Robert Roessle Klinik
- Registration Number
- NCT00004150
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇫🇷CHR de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷Centre Hospitalier de Bourgoin - Jallieu, Bourgoin-Jallieu, France
Combination Chemotherapy in Treating Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Registration Number
- NCT00039208
- Locations
- 🇫🇷
Hopital Saint-Louis, Paris, France
🇫🇷Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷Centre Hospital Regional Universitaire de Limoges, Limoges, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.